inPractice® - Implantable, Intravaginal, and Intrauterine Contraceptives

Special Considerations in the Management of Women With HIV, Including Management of Conception and Pregnancy

Author: Kristine Patterson, MD (More Info)
Section Editor: Judith S. Currier, MD, MSc
Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
Last Reviewed: 8/30/19 (What's New)

Summary

All combined hormonal contraceptive methods are listed as Category 1 (no restriction for use) for women at high risk for HIV or with HIV or AIDS by the CDC Medical Eligibility Criteria for Contraceptive Use^{[CDC MEC; CDC MEC Summary]}
Efavirenz may decrease etonogestrel and levonorgestrel levels attained from implants^{[DHHS Perinatal; Leticee 2012; Scarsi 2015]}
Cobicistat may increase estrogen and progestin levels

Action required

Login now to access all of your entitled content
or
View additional options to gain access to this content

Keywords: Drug-Drug Interactions, Pregnancy, Women